Nymox claims “success” in Phase II trial of NX-1207 in low-risk prostate cancer

Posted on February 9, 2016 by Sitemaster

According to a media release issued today by Nymox Pharmaceutical Corp., their investigational drug NX-1207 (now properly known by the generic name fexapotide triflutate) successfully met the designated endpoints for a Phase II clinical trial of this drug in treatment of men with low-grade, localized prostate cancer. … READ MORE …

Filed under: Drugs in development | Tagged: , , , | 10 Comments »

NX-1207 not effective in treatment of BPH

Posted on November 3, 2014 by Sitemaster

As regular readers will be aware, Nymox Pharmaceutical has been developing a drug called NX-1207 for the treatment of benign prostatic hypertrophy (BPH) and for the treatment of localized prostate cancer. … READ MORE …

Filed under: Diagnosis, Drugs in development, Management, Treatment | Tagged: , , | 1 Comment »

  • Donate

  • Disclaimer

    News and information provided on this site should not be used for diagnosing or treating any health problem or disease.

    The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.

  • Hot Posts …

  • … and Archives